Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd. transitioned into NewcelX Ltd. after its completed merger with Kadimastem, creating a clinical-stage biotechnology company focused on cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. Recurring news includes scientific advisory board updates, clinical-development themes in ALS and AstroRx, CNS pipeline additions such as the AEX-6xx series, and diabetes-program references including ITOL-102.
Company updates also cover material agreements, shareholder voting matters, capital-structure disclosures, governance changes, clinical or regulatory communications, and operating and financial results tied to the combined biotechnology business.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.